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INTRODUCTION 
 
Tissue engineering actual tendencies leads to the development of biocompatible 
matrices with accurate physical and mechanical properties in bone reconstruction. As a 
regeneration of a new tissue is achieved, the scaffold is no longer needed and so it is 
reasonable to use biodegradable scaffolds [1]. The rate of degradation must be in parallel 
with the tissue regeneration, and is very important to provide long term construct 
biocompatibility, because only natural tissue will remain in the body–a neo-organ. In this 
context one of the most common compound used is the natural polymer chitosan, whose 
mechanical properties can be improved by adding synthetic polymers [2]. The great 
interest in this macromolecule is due to its proved biocompatibility and biodegradation 
properties [3].  
Matrix also requires the capacity to transport osteogenic agents which enhance bone 
regeneration. Bisphosphonates are a new class of synthetic compounds structurally related 
to pyrophosphate, an endogenous modulator in homeostasis of calcium, and they are 
clinically used for various metabolic bone disorders such as Paget’s disease, hypercalcemia 
of malignancy, bone metastasis and osteoporosis [4]. The reduced targetability of some 
bisphosphonates in relationship to the dose increased and its hepatosplenic accumulation 
has been reported [5]. It is due to high precipitability with divalent ions in the circulation in 
blood plasma, which may be taken up by reticuloendothelial system as foreign substances 
[6]. Therefore, new drug delivery systems are needed to overcome these problems.  
The aim of our work is the development of a scaffold for tissue engineering based in 
chitosan/poly-ε-caprolactone blend which contains an adequate concentration of 
alendronate (a nitrogen bisphosphonate) for osteoblastic bone growth without toxic effects.  
 
MATERIALS and METHODS 
 
Materials. High molecular weight Chitosan (Ch) and poly-ε-caprolactone (PECL) 
were purchased from Aldrich. The viscometric average molecular weight of Ch is 780 kD 
and 21% DA (determined by FTIR). Weight average molecular weight and polydispersity 
index of PECL is 65000 and 1.4 respectively, as indicating by the manufacturing. Tissue 
culture flasks and dishes were purchased from Corning (Princeton, NJ, USA); Dulbecco’s 
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Modified Eagles Medium (DMEM) and trypsin-EDTA were purchased from Gibco 
(Gaithersburg, MD, USA). Fetal bovine serum (FBS) was obtained from Gen (Buenos 
Aires, Argentina). 
Matrices preparation. Blend of PECL and chitosan were prepared by solvent casting 
according to Sarasam et al [7]: 9 ml of a polyester solution in acetic acid (0.3 % w/w) were 
added to 3 ml of 0.5% w/v of chitosan in dilute acetic acid (3 % v/v). Blends with different 
concentrations of alendronate were prepared (1, 2, 5, 10 % w/w), designed as ChEA1, 
ChEA2, ChEA5 and ChEA10 respectively. The solution of the blend were poured onto 
glass Petri dishes (5 cm diameter), and the solvent was allowed to evaporate at room 
temperature, then under vacuum until constant weight, and stored in desiccators until use. 
Matrix characterization. Scanning electronic microscopy (SEM) was employed to 
observe the morphology of the matrices .The surfaces of the matrices were coated with 
gold and their morphology was examined using scanning electron microscopy (SEM, 
Phillips505, Holland), with a accelerating voltage of 20 kV, and the images were analyzed 
by Soft Imaging System ADDAII. FTIR spectra of films were recorded on a Nicolet 380 
FTIR between 4000-400 cm-1 with a resolution of 4 cm-1 and 32 scans of accumulation. 
EZ-OMNIC software was used by analyzed the spectra.  
Biocompatibility studies. Matrices of the blends were sterilized with UV radiation 
before cells seeding. UMR106 osteosarcoma rat cells in the culture flask were grew to be 
confluent in DMEM containing 10 % FBS, 100 U/ml penicillin and 100 µg/ml 
streptomycin at 37ºC in a 5 % CO2 atmosphere [8]. Cells were sub-cultured using trypsin-
EDTA. The UMR106 cell line has been shown to conserve certain characteristics of 
differentiated osteoblastic phenotype [9]. For the different experiments, cells were seeded 
on polymeric matrix-coated dishes and incubated in 10% FBS medium for 24 hours.  
Cell growth was estimated by staining the cells with Giemsa [10].  
Cellular differentiation was investigated after 24 o 48 h culture by means of collagen 
production (Sirius red stain) and osteoblast marker Alkaline phosphatase (ALP). For ALP 
marker cells were lysed with 0,1% Triton – X100. We determined protein content (by 
Bradford Method) and ALP specific activity (by p-nitrophenyl phosphate to p-nitrophenol 
hydrolysis) with the extract aliquots. 
 
RESULTS and DISCUSSION 
 
Blending Ch/PECL with different concentration of alendronate allowed us obtaining 
slightly porous matrices with well interconnected pores as shown by SEM images in 
Figure 1(A and B). 
 
 (A)      (B) 
      
 
Figure 1. ChE (A) and ChEA (B) matrix surface. Magnification x 600. 
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The superficial characterization of the ChE and ChEA matrices showed a change in 
micromorphology as the amount of alendronate in the blend increases. The ChE matrix 
(Fig. 1A) shows more irregular surface morphology than that of the ChEA. It is quite 
different in the case of the matrices containing alendronate, with ChEA2 (Fig. 1B) 
presenting a skeletal structure composed of small platelet-balls.  
The FTIR spectra of Ch, ChE and ChEA2 are shown in Figure 2 between 1900 and 
400 cm-1. Chitosan spectrum show two typical bands at 1640 and 1556 cm-1 attributed to 
amide I and amide II respectively. The spectra of blends exhibited a characteristic band of 
carbonyl group of PECL at 1725 cm-1 and a shoulder at about 1690 cm-1. This shoulder 
band is attributable to the hydrogen bonded carbonyl groups with hydrogen-donating 
groups (–OH and –NH2) of Ch, as was observed by other researches [11]. In addition, the 
bands at 1315 cm-1 (stretching vibration of C-N of Ch) and 1377 cm-1 (bending vibration of 
O-H of Ch) showed shifted to lower wave numbers in the blends, 1294 and 1369 cm-1 
respectively. These observation can also be attributed to hydrogen bond and demonstrate 
that physical interaction are present in the chitosan-poly-ε-caprolactone blends. The area 
analysis of 1556 and 1640 cm-1 bands (data not show) evince a significant change related 
with the chitosan-alendronate ionic interaction.  
 
 
 
Figure 2. FTIR of Ch, ChE and ChEA2. 
 
Cells grew well into the matrices showing normal morphology, being able to adhere 
and proliferate well on all the investigated matrices. 
Cells growth well on the ChE film and were included diaper into the matrix (Figure 
3A). The addition of alendronate in the ChE matrix induced a dose-dependent inhibition in 
the cell proliferation (Figure 3B and 3C).  
 
(A)    (B)    (C) 
      
 
Figure 3. Microphotograph of UMR106 cells growing on ChE (A), ChEA2 (B) and ChEA5 (C), stained 
with Giemsa. Obj. 10X 
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We also evaluated the osteoblastic differentiating capacity of cells growing on 
different matrices. Figure 4 shows the expression of ALP, an osteoblastic marker, after 48h 
of culture. As can be seen, alendronate induce a dose-dependent reduction in this marker.  
 
Figure 4. Effect of alendronate on ALP activity of UMR106 cell growing on different matrix  
 
This observation suggests that although the polymeric films were able to support the 
progression of the cells, the alendronate probably released in the medium was exerting a 
cytotoxic effect. We have previously shown a similar inhibitory effect when UMR106 cells 
were cultured in the presence of 10-5-10-4 M alendronate, suggesting a toxic effect [12].  
Although we do not directly evaluate the alendronate released into the medium, it could be 
estimated that the ChEA2 matrix should release at less 10-5 M alendronate after for 48 
hours of culture.  
Our results, although preliminary, shows that mixed matrices prepared starting of 
chitosan and poly-ε-caprolatone blends presents slightly porous structure with good  
interpolymeric interactions and biocompatibility. The inclusion of alendronate exerts a 
dose-dependent inhibitory effect on the cell progression. With regard to this aspect, further 
in vitro experiments are in progress in order to investigate and develop controlled release 
system of alendronate.  
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